Purple Biotech (NASDAQ:PPBT) and Summit Therapeutics (NASDAQ:SMMT) Financial Analysis

Purple Biotech (NASDAQ:PPBT) and Summit Therapeutics (NASDAQ:SMMT) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, risk, valuation, earnings and dividends.

Analyst Recommendations

This is a summary of current ratings for Purple Biotech and Summit Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Purple Biotech	1	1	1	0	2.00
Summit Therapeutics	2	6	7	1	2.44

Purple Biotech currently has a consensus target price of $30.00, suggesting a potential upside of 1,971.82%. Summit Therapeutics has a consensus target price of $26.15, suggesting a potential upside of 87.96%. Given Purple Biotech’s higher probable upside, equities analysts plainly believe Purple Biotech is more favorable than Summit Therapeutics.

Earnings and Valuation

This table compares Purple Biotech and Summit Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Purple Biotech	N/A	N/A	-$26.39 million	($18.84)	-0.08
Summit Therapeutics	N/A	N/A	-$1.08 billion	($1.12)	-12.42

Summit Therapeutics is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

9.6% of Purple Biotech shares are owned by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are owned by institutional investors. 3.0% of Purple Biotech shares are owned by company insiders. Comparatively, 83.5% of Summit Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Volatility and Risk

Purple Biotech has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500. Comparatively, Summit Therapeutics has a beta of -1.26, meaning that its share price is 226% less volatile than the S&P 500.

Profitability

This table compares Purple Biotech and Summit Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Purple Biotech	N/A	-123.63%	-98.72%
Summit Therapeutics	N/A	-168.94%	-141.92%

Summary

Purple Biotech beats Summit Therapeutics on 7 of the 12 factors compared between the two stocks.

About Purple Biotech

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.

About Summit Therapeutics

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company’s lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.